DURHAM, NC & SEATTLE, WA, USA I November 14, 2024 ILeading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initi...
Based in Durham, Nc. and Seattle, Wa., Tune was founded and built around a veteran leadership team with expertise in gene and cell therapy, genome editing, and epigenetics
Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common, chronic and age-related diseases that are straining healthcare systems and limiting human healthspa
Materials and methods Cell Lines and Reagents Ovarian epithelial carcinoma cell lines HEYA8, SKOV-3, and OVCA-429 were obtained from the Duke Gynecology/Oncology Bank (Durham, NC) and ATCC (ATCC® HTB-77™). CHO-K1 epithelial cell lines pgsA-745 (ATCC® CRL-2242™), and pgsD-677 ...